- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial

AstraZeneca’s Farxiga is an SGLT2 inhibitor used for treating patients with type-2 diabetes. Credit: AstraZeneca.